Karyopharm Therapeutics Inc. (KPTI)
NASDAQ: KPTI · Real-Time Price · USD
8.48
-0.29 (-3.31%)
Mar 9, 2026, 4:00 PM EDT - Market closed
Karyopharm Therapeutics Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2016 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2020 - 2016 |
| Revenue | 146.07 | 145.24 | 146.03 | 157.07 | 209.82 | Upgrade
|
| Revenue Growth (YoY) | 0.57% | -0.55% | -7.03% | -25.14% | 94.12% | Upgrade
|
| Cost of Revenue | 131.57 | 149.24 | 143.69 | 153.88 | 3.4 | Upgrade
|
| Gross Profit | 14.5 | -4 | 2.34 | 3.2 | 206.42 | Upgrade
|
| Selling, General & Admin | 105.21 | 115.44 | 131.88 | 145.4 | 143.85 | Upgrade
|
| Research & Development | - | - | - | - | 160.84 | Upgrade
|
| Operating Expenses | 105.21 | 115.44 | 131.88 | 145.4 | 304.69 | Upgrade
|
| Operating Income | -90.71 | -119.44 | -129.54 | -142.2 | -98.27 | Upgrade
|
| Interest Expense | -45.85 | -37.42 | -23.82 | -25 | -26.05 | Upgrade
|
| Interest & Investment Income | 2.77 | 7.4 | 10.94 | 2.36 | 0.58 | Upgrade
|
| Other Non Operating Income (Expenses) | 0.15 | 28.4 | -0.36 | -0.08 | -0.09 | Upgrade
|
| EBT Excluding Unusual Items | -133.63 | -121.07 | -142.78 | -164.92 | -123.82 | Upgrade
|
| Other Unusual Items | -62.37 | 44.7 | - | - | - | Upgrade
|
| Pretax Income | -196 | -76.37 | -142.78 | -164.92 | -123.82 | Upgrade
|
| Income Tax Expense | 0.04 | 0.06 | 0.32 | 0.37 | 0.27 | Upgrade
|
| Net Income | -196.04 | -76.42 | -143.1 | -165.29 | -124.09 | Upgrade
|
| Net Income to Common | -196.04 | -76.42 | -143.1 | -165.29 | -124.09 | Upgrade
|
| Shares Outstanding (Basic) | 11 | 8 | 8 | 5 | 5 | Upgrade
|
| Shares Outstanding (Diluted) | 11 | 8 | 8 | 5 | 5 | Upgrade
|
| Shares Change (YoY) | 29.33% | 11.02% | 39.54% | 8.85% | 4.41% | Upgrade
|
| EPS (Basic) | -17.93 | -9.41 | -18.79 | -30.28 | -24.75 | Upgrade
|
| EPS (Diluted) | -17.93 | -14.00 | -18.79 | -30.30 | -24.75 | Upgrade
|
| Free Cash Flow | -75.37 | -127.63 | -92.72 | -149.67 | -107.33 | Upgrade
|
| Free Cash Flow Per Share | -6.89 | -15.10 | -12.18 | -27.42 | -21.40 | Upgrade
|
| Gross Margin | 9.93% | -2.76% | 1.60% | 2.04% | 98.38% | Upgrade
|
| Operating Margin | -62.10% | -82.24% | -88.71% | -90.53% | -46.84% | Upgrade
|
| Profit Margin | -134.21% | -52.62% | -97.99% | -105.23% | -59.14% | Upgrade
|
| Free Cash Flow Margin | -51.60% | -87.88% | -63.50% | -95.29% | -51.15% | Upgrade
|
| EBITDA | -90.41 | -119.1 | -129.01 | -141.58 | -97.48 | Upgrade
|
| EBITDA Margin | -61.90% | -82.01% | -88.34% | -90.14% | -46.46% | Upgrade
|
| D&A For EBITDA | 0.3 | 0.34 | 0.53 | 0.62 | 0.79 | Upgrade
|
| EBIT | -90.71 | -119.44 | -129.54 | -142.2 | -98.27 | Upgrade
|
| EBIT Margin | -62.10% | -82.24% | -88.71% | -90.53% | -46.84% | Upgrade
|
| Revenue as Reported | 146.07 | 145.24 | 146.03 | 157.07 | 209.82 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.